The Securities and Exchange Commission is investigating whether Cecil-based Mylan Inc. disclosed confidential information about earnings to a select group of analysts in violation of the agency's fair disclosure rules, according to a report this morning in the Wall Street Journal.
The day after the Sept. 9 meeting, at which Mylan CEO Robert Coury and President Heather Bresch were scheduled to speak, the generic drug giant's shares jumped 7 percent.
Mylan didn't immediately respond to the Post-Gazette's requests for comment. The SEC declined comment.
The SEC has contacted several investment banks whose analysts follow Mylan asking about the meeting, the Journal said.
Following the meeting, some analysts in attendance issued reports to clients saying they were encouraged by management's comments.
"We have become incrementally more positive on Mylan's third-quarter [earnings per share] outlook," analysts at J.P. Morgan wrote after the meeting.
Mylan released third-quarter earnings Oct. 29, beating analysts' expectations.
The meeting, held in Morgantown, W.Va., where Mylan operates a major drug-making plant, came the day after the company announced the departure of its chief financial officer, Jolene Varney, after three months on the job.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.